Pharmacological and non-pharmacological therapies for adults with attention-deficit/hyperactivity disorder: systematic review and meta-analysis of clinical evidence
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001514
English
Authors' recommendations:
The available evidence suggests that amphetamine, methylphenidate, atomoxetine, cognitive behavioural therapy, and meta-cognitive therapy are associated with greater attention-deficit/hyperactivity disorder symptom reduction compared with placebo or supportive therapy. The evidence also suggests that the use of methylphenidate is associated with better functioning and cognitive skills than placebo. Large, well-designed trials that specifically address the treatment of attention-deficit/hyperactivity disorder in adults are needed to accurately assess the impacts on quality of life and attention-deficit/hyperactivity disorder-associated morbidities.
Details
Project Status:
Completed
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Adult
- Attention Deficit Disorder with Hyperactivity
- Psychotherapy
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.